A long-term clinical follow-up of children with acute lymphoblastic leukemia treated with intensive chemotherapy regimens.
One hundred and thirty-three children 15 years old and younger with acute lymphoblastic leukemia were treated with two different protocols. Both regimens consist of a multi-drug program, without CNS irradiation, administered for three years. Seventy-five children were enrolled on the first protocol, L-2; and 58 were treated on the subsequent regimen, L-10. Of the 70 evaluable patients on the L-2 program, 40 continue in complete remission from 72-111 months. Seventy-four percent of the children qualified for treatment cessation, and 59% have remained in continuous remission for six years. The estimated seven year disease-free survival for the 70 evaluable children on the L-2 protocol is 57% and for all entries is 53%. Of the 57 evaluable patients on the L-10 program, 35 are in complete remission from 15-67 months. The combined frequency of primary CNS leukemia for the two regimens is 7%. The off-therapy results of the L-2 protocol cannot be compared to the L-10 at present, but the on-therapy outcomes, despite the modifications that were designed to improve the L-10 regimen, are comparable.
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D009423:Nervous System Neoplasms / Q000453:epidemiology; D011379:Prognosis; D012008:Recurrence; D013736:Testicular Neoplasms / Q000453:epidemiology; D013921:Thrombocytopenia / Q000139:chemically induced
D000970:Antineoplastic Agents